vTv Therapeutics Inc
NASDAQ:VTVT

Watchlist Manager
vTv Therapeutics Inc Logo
vTv Therapeutics Inc
NASDAQ:VTVT
Watchlist
Price: 32.26 USD 5.74% Market Closed
Market Cap: 127.1m USD

vTv Therapeutics Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

vTv Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
vTv Therapeutics Inc
NASDAQ:VTVT
Revenue
$17k
CAGR 3-Years
-80%
CAGR 5-Years
-11%
CAGR 10-Years
-35%
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

vTv Therapeutics Inc
Glance View

Market Cap
127m USD
Industry
Biotechnology

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 9 full-time employees. The company went IPO on 2015-07-30. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non- central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Nrf2/Bach1 Modulator Program.

VTVT Intrinsic Value
HIDDEN
Show

See Also

What is vTv Therapeutics Inc's Revenue?
Revenue
17k USD

Based on the financial report for Sep 30, 2025, vTv Therapeutics Inc's Revenue amounts to 17k USD.

What is vTv Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
-35%

Over the last year, the Revenue growth was -98%. The average annual Revenue growth rates for vTv Therapeutics Inc have been -80% over the past three years , -11% over the past five years , and -35% over the past ten years .

Back to Top